Last reviewed · How we verify
MDX1303
At a glance
| Generic name | MDX1303 |
|---|---|
| Sponsor | PharmAthene, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects (PHASE1)
- Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use (PHASE1)
- Ph1 Study of Valortim and Doxycycline in Humans (PHASE1)
- Ph1 Study of Valortim and Ciprofloxacin in Humans (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDX1303 CI brief — competitive landscape report
- MDX1303 updates RSS · CI watch RSS
- PharmAthene, Inc. portfolio CI